Bryan Kobel

Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members.

Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ.

Expedeon Ltd. develops and produces proteins for drug discovery. Its products include gel electrophoresis, nucleic acid kits, protein quantitation, western blotting reagents and spectroscopy. The firm provides genomics and proteomics tools to scientists. The company was founded by Heikki Lanckriet in 2003 and is headquartered in Cambridge, the United Kingdom.

Cowen Prime Services LLC (CPS) is a broker-dealer headquartered in New York City. The firm is directly owned by Cowen PB Holdings LLC, which, in turn, is primarily owned by Cowen Group, Inc. (NASDAQ: COWN). CPS is registered as a broker-dealer with the SEC and FINRA, and as a an introducing broker with the Commodities Futures Trading Commission and the National Futures Association. CPS was formed in 2015 following Cowen Group’s acquisition of Concept Capital Markets LLC. Concept Capital was established in 2010 following the spin-off of the Concept Capital division of Sanders Morris Harris Inc., whose origins date back to 1995. CPS' offering includes world-class custody and clearing options, multi asset class capabilities, leading execution and order management systems, a seasoned execution desk, a range of financing options, a highly professional operations and customer support team, comprehensive portfolio reporting capabilities, capital introduction, and live, intraday and post-trade risk and performance analytics.

Safeguard Biosystems Holdings Ltd. engages in the development, manufacture, and sales of diagnostic tests for human and animal health; and food safety products. The company was founded on May 11, 2006 and is headquartered in London, the United Kingdom.

Jefferies International Ltd. (JIL) is a brokerage firm headquartered in London, UK. The firm was founded in 1986 and is a subsidiary of Jefferies Holdings II Ltd., ultimately held by Jefferies Financial Group, Inc. (NYSE: JEF) in the US. JIL provides broking services to various investors.

TC Biopharm Ltd. provides research services. The firm specializes in clinical grade cell therapy, cancer immonotherapy, regenerative medicine, and stratified medicine. The company was founded by Michael Leek, Angela Scott and David Galagher in 2014 and is headquartered in Edinburgh, the United Kingdom.

Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom.

ToHealth Ltd. provides health and wellbeing services. The private company is based in London, UK. The CEO of the British company is Robin Skinner.

Luperacus Ltd. develops novel therapeutic antibodies to treat canine and human cancer. The company was founded by Alan G. Clark and is headquartered in Glasgow, the United Kingdom.

Aerwave Medical, Inc. is a company that is developing a unique alternative to traditional medications used to treat pulmonary diseases such as asthma and COPD. The company is based in New York, NY, and the CEO of the company is Jeffrey Francis O'Donnell. These diseases are characterized by an unmet medical need, with up to 15% of asthma patients and 25% of COPD patients being unresponsive to treatment. Additionally, around 50% of long-term inhaler users discontinue use within the first year due to compliance issues and multiple side effects. Aerwave Medical's revolutionary approach involves an interventional method to treat these diseases.

Hox Therapeutics Ltd. develops therapeutics for cancer diseases based on the role of HOX genes. The private company is based in Guildford, UK.

Algorithm Sciences, Inc. engages in the business of technology services. The company was founded in 2019 and is headquartered in New York, NY.

ILC Therapeutics Ltd. is a British biotechnology company that conducts research and experimental development. The company is based in Lanarkshire, UK. The company was founded by William H. Stimson. Alan Keith Walker has been the CEO of the company since 2020.

Glykogen Ltd. engages in the development of anti-glycan monoclonal antibodies using a novel and innovative process. The company was founded on October 11, 2016 and is headquartered in Fife, the United Kingdom.